TCB008

Phase 2Small molecule

TTC Biopharm

TCB008 is one of 80 small molecule programs targeting Myelodysplastic Syndrome. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myelodysplastic SyndromeActive, not recruiting

COVID-19Active, not recruiting

Myelodysplastic SyndromePhase 1

Active, not recruiting

COVID-19Phase 2

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Spikevax

Moderna

Preclinical

21 2

Bnt162b2

BioNTech

Preclinical

29 3

TCB008

TTC Biopharm

Phase 2

1 4

Rayaldee

OOrganon and Co

Preclinical

1 5

Statins

Sanofi

Preclinical

1 6

Nadroparin

GSK

Preclinical

1 7

Glucocorticoid

AbbVie

Preclinical

1 8

Calcium

Eli Lilly

Preclinical

—9

HB-Admscs

HHope Biosciences Research Foundation

Preclinical

4 10

Olokizumab

UCB

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Not yet recruiting

Myelodysplastic Syndrome

NCT06463327

Clinical

Trials by Indication[1]

Acute Myeloid Leukaemia (AML)1 trial

ACHIEVE - Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded Allogeneic γδ T-lymphocytes (TCB008) for Patients With Refractory or Relapsed Acute Myeloid Leukaemia (AML)

Terminated·TTC Biopharm·Phase 2·NCT05358808·16 enrolled

COVID-191 trial

A Phase II Safety and Tolerability Study of TCB008 in Patients With COVID-19

Withdrawn·TTC Biopharm·Phase 2·NCT04834128

Myelodysplastic Syndrome1 trial

ACHIEVE2 - Safety and Preliminary Efficacy of Intravenous TCB008 in Patients With Relapse or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)/AML

Not yet recruiting·TTC Biopharm·Phase 1·NCT06463327·69 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for TCB008. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TCB008 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TCB008. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — TC Biopharm company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TTC Biopharm

TCB008

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Acute Myeloid Leukaemia (AML)1 trial

COVID-191 trial

Myelodysplastic Syndrome1 trial

References

Drug Info

Quick Facts

Related News